Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Thomas Jefferson University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07188090CT.gov Mozobil for Autologous Hematopoietic Stem Cell Transplantation | — | Recruiting | — | — | — |
NCT06207799CT.gov Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | — | Recruiting | — | — | — |
NCT04552743CT.gov MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | — | Completed | — | — | — |
NCT03506802CT.gov TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03244930CT.gov Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation | — | Unknown | — | — | — |
NCT03406091CT.gov Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients | — | Completed | — | — | — |
NCT02682953CT.gov Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers | — | Withdrawn | — | — | — |
NCT02221479CT.gov Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma | — | Completed | — | — | — |
NCT02098109CT.gov Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01610999CT.gov Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation | — | Terminated | — | — | — |
Show 29 more trialsShow fewer
NCT01753453CT.gov An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells | — | Completed | — | — | — |
NCT01547806CT.gov Collection of Transplant Stem Cells for Plasma Cell Myeloma | — | Completed | — | — | — |
NCT01526096CT.gov Stem Cell Transplantation for Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01301963CT.gov Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide | — | Terminated | — | — | — |
NCT01339572CT.gov Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation | — | Completed | — | — | — |
NCT01158118CT.gov Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | — | Completed | — | — | — |
NCT01146834CT.gov Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | — | Completed | — | — | — |
NCT01076270CT.gov Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | — | Terminated | — | — | — |
NCT01186224CT.gov Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) | — | Completed | — | — | — |
NCT01074060CT.gov Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01220375CT.gov PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma | — | Completed | — | — | — |
NCT01095757CT.gov Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection | — | Completed | — | — | — |
NCT01042717CT.gov Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | — | Unknown | — | — | — |
NCT01037517CT.gov Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization | — | Completed | — | — | — |
NCT00998049CT.gov Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | — | Completed | — | — | — |
NCT00903968CT.gov Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00901225CT.gov Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant | — | Completed | — | — | — |
NCT01700608CT.gov Prospective Observational Study on Plerixafor After Chemotherapy | — | Completed | — | — | — |
NCT00665314CT.gov Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | — | Completed | — | — | — |
NCT00741780CT.gov Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). | — | Completed | — | — | — |
NCT00395967CT.gov AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | — | Terminated | — | — | — |
NCT00103662CT.gov Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00396266CT.gov AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | — | Completed | — | — | — |
NCT00396383CT.gov Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation | — | Terminated | — | — | — |
NCT00322842CT.gov Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00241358CT.gov Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT00322387CT.gov Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients | — | Completed | — | — | — |
NCT00322491CT.gov Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00720603CT.gov This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Plerixafor (this asset) | Thomas Jefferson University | P3 | B · 60 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Plerixafor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fanconi Anemia | — | P2 | BB · 70 |
| Hodgkins Lymphoma | — | P2 | BB · 70 |
| Non-Hodgkin Lymphoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Plerixafor in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/plerixafor-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →